Published in Cancer on October 01, 1969
Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity. Proc Natl Acad Sci U S A (1980) 2.35
Long term effects of radiation of T and B lymphocytes in peripheral blood of patients with Hodgkin's disease. J Clin Invest (1976) 1.59
MVPP chemotherapy regimen for advanced Hodgkin's disease. Br Med J (1978) 1.46
Hodgkin's disease and other malignant lymphomas. Calif Med (1970) 1.42
Staging laparotomy in non-Hodgkin's lymphoma. Br J Cancer Suppl (1975) 1.30
Observations on abnormal cells in the peripheral blood and spleen in Hodgkin's disease. Br Med J (1972) 1.10
An antigen in Hodgkin's disease tissue cultures: fluorescent antibody studies. Proc Natl Acad Sci U S A (1974) 1.09
The results of radiotherapy for Hodgkins' disease. Br J Cancer (1975) 1.06
Does the surgeon still have a role to play in the diagnosis and management of lymphomas? World J Surg Oncol (2008) 1.06
Accuracy of laparoscopy in the diagnosis and staging of lymphoproliferative diseases. World J Surg (2003) 1.05
Splenectomy in hematologic disorders. The ever-changing indications. Ann Surg (1988) 1.02
Radiotherapy in the treatment of Hodgkin's disease. Br Med J (1978) 1.01
The pathological findings following laparotomy in Hodgkin's disease. Br J Cancer (1971) 0.92
Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer (2004) 0.90
Staging laparotomy in Hodgkin's disease. Ann Surg (1978) 0.89
Hodgkin's disease presenting as liver abscesses. Gut (1991) 0.87
Lymph node biopsy during laparotomy for the staging of Hodgkin's disease. Ann Surg (1973) 0.81
Prognostic effect of early diagnostic splenectomy in Hodgkin's disease: a randomized trial. Br J Cancer (1980) 0.80
E-rosette inhibiting substance in Hodgkin's disease spleen extracts. Clin Exp Immunol (1977) 0.79
The diagnosis of Hodgkin's disease in surgically excised spleens. J Clin Pathol (1972) 0.78
Prognostic significance of primary site after radiotherapy in non-Hodgkin's lymphomata. Br J Cancer Suppl (1975) 0.75
Reevaluation of alkaline phosphatase measurement during Hodgkin's disease by electrophoretic isoenzyme separation. Br J Cancer (1985) 0.75
Acute myelomonocytic leukemia following splenectomy in a patient with long-standing Hodgkin disease. West J Med (1978) 0.75
Hodgkin's disease in adults: the challenge. Postgrad Med J (1985) 0.75
Management of Hodgkin's disease in childhood. Arch Dis Child (1977) 0.75
The place of laparotomy in the management of pyrexia of unknown origin. Ann R Coll Surg Engl (1972) 0.75
[Scleronodular type of Hodgkin's disease: experience at the Sherbrooke University Hospital Center]. Can Med Assoc J (1974) 0.75
Post-mortem findings in Ugandans with Hodgkin's disease. Br J Cancer (1972) 0.75
Staging laparotomy in Hodgkin's disease. Ann Surg (1980) 0.75
Hodgkin's disease: prognosis as related to pathology, staging and treatment. Proc R Soc Med (1972) 0.75
Hodgkin's disease--I: Identification and classification. BMJ (1992) 0.75
Improved survival time trends in Hodgkin's lymphoma. Cancer Med (2016) 0.75
Medical staff conference: Hodgkin disease. West J Med (1977) 0.75
Surgical pathology of the spleen. Ann R Coll Surg Engl (1975) 0.75
Correlation of anemia with infradiaphragmatic involvement in Hodgkin's disease and other malignant lymphomas. Can Med Assoc J (1974) 0.75
Evolution of lymphoma staging and response evaluation: current limitations and future directions. Nat Rev Clin Oncol (2017) 0.75
Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res (1971) 13.16
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A (1994) 8.92
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med (1982) 8.74
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 8.07
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A (1994) 6.93
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother (2001) 5.83
Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol (1998) 5.74
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med (1994) 5.67
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol (1989) 5.44
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24
Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science (1984) 4.90
On the natural history of the murine leukemias: presidential address. Cancer Res (1967) 4.79
Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases. Cancer (1973) 4.66
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 4.42
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am (2000) 4.19
The attributes of medical event-reporting systems: experience with a prototype medical event-reporting system for transfusion medicine. Arch Pathol Lab Med (1998) 4.03
Of scientific physicians and evidence-based medicine. Int J Radiat Oncol Biol Phys (2001) 3.94
Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med (1994) 3.94
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A (1999) 3.66
Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol (1989) 3.60
Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts. J Exp Med (1977) 3.48
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol (1996) 3.45
Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med (1995) 3.43
Identification of human cancers deficient in antigen processing. J Exp Med (1993) 3.21
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods (1987) 3.09
Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (1984) 3.08
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med (1997) 3.07
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med (1985) 3.05
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol (2001) 3.05
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol (1998) 3.03
Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol (1987) 3.03
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med (1996) 2.99
The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med (1984) 2.95
High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol (1999) 2.94
Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol (1986) 2.82
Rhabdomyosarcoma. A new classification scheme related to prognosis. Arch Pathol Lab Med (1992) 2.79
Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res (1994) 2.74
In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol (1985) 2.73
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am (1997) 2.71
Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med (1983) 2.67
Replication kinetics of N- and B-tropic murine leukemia viruses on permissive and nonpermissive cells in vitro. Virology (1975) 2.62
Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol (1994) 2.59
Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clin Oncol (2001) 2.55
Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med (1995) 2.54
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res (1981) 2.49
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol (1995) 2.45
Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med (1982) 2.42
DNA polymerase required for rapid repair of x-ray--induced DNA strand breaks in vivo. Science (1971) 2.39
Monocyte dependence of pokeweed mitogen-induced differentiation of immunoglobulin-secreting cells from human peripheral blood mononuclear cells. J Immunol (1979) 2.36
Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity. Proc Natl Acad Sci U S A (1980) 2.35
Passive immunotherapy of cancer in animals and man. Adv Cancer Res (1977) 2.32
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med (1996) 2.31
Comparison of computed and conventional whole lung tomography in detecting pulmonary nodules: a prospective radiologic-pathologic study. AJR Am J Roentgenol (1978) 2.29
Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Natl Acad Sci U S A (1985) 2.26
Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med (1988) 2.26
Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol (1992) 2.19
Structural characteristics of some murine RNA tumor viruses studied by lactoperoxidase iodination. Proc Natl Acad Sci U S A (1973) 2.18
Isolation of a type C RNA virus from an established human histiocytic lymphoma cell line. Proc Natl Acad Sci U S A (1977) 2.18
Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol (1999) 2.17
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med (1996) 2.17
DNA-strand scission and loss of viability after x irradiation of normal and sensitized bacterial cells. Proc Natl Acad Sci U S A (1966) 2.16
Surgical staging of abdominal involvement in unselected patients with Hodgkin's disease. Radiology (1970) 2.16
Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol (1996) 2.15
Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am (1998) 2.14
Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med (1991) 2.14
The fate of interleukin-2 after in vivo administration. J Immunol (1983) 2.13
Antigen processing in vivo and the elicitation of primary CTL responses. J Immunol (1995) 2.12
Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci U S A (1997) 2.11
Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst (1996) 2.11
Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol (1986) 2.08
T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. Cancer J (2001) 2.08
Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am (2000) 2.06
Characterization of the reverse transcriptase of a type C RNA virus produced by a human lymphoma cell line. Proc Natl Acad Sci U S A (1979) 2.03
IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol (1995) 2.02
Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science (1999) 2.01
Is meta-analysis really meta-physics? Chest (1999) 2.00
Evidence for an orderly progression in the spread of Hodgkin's disease. Cancer Res (1966) 2.00
Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol (1989) 2.00
Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res (1996) 1.99
Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med (1983) 1.99
Clinical evaluation and radiotherapeutic management of Hodgkin's disease and the malignant lymphomas. N Engl J Med (1968) 1.99
Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med (1988) 1.98
Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today (1988) 1.97
The protein of human erythrocyte membranes. I. Preparation, solubilization, and partial characterization. J Biol Chem (1968) 1.97
CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci U S A (2001) 1.96